Table 8 PLR studies related to treatment toxicities
Year | Article | Total N | Study end-point(s) | Disease(s) | Treatment(s) | Important results |
|---|---|---|---|---|---|---|
2020 | Han et al. [81] | 379 | EF | Esophageal ca. | CRT | High pretreatment PLR (> 153) was the independent factor of EF in multivariate analysis; PLR-based nomogram significantly predicted EF |
2021 | Yang et al. [82] | 174 | RP | Esophageal ca. | (C)RT | PLR (≥ 523.78) during 3–4 weeks of RT was the independent predictor of symptomatic RP in multivariate analysis; PLR including nomogram significantly predicted symptomatic RP |
2022 | Huang et al. [83] | 84 | OS, PFS, RP | NSCLC | (C)RT/(C)RT + durvalumab | Week 6 PLR ≥ 180 was associated with a lower risk of pneumonitis; week 6 PLR (continuous) was the independent indicator of PFS. |
2022 | Qui et al. [84] | 187 | Severe radiation esophagitis (≥ Gr2) | SCLC | (C)RT | Pretreatment high PLR (≥ 231.1) was the predictor of severe RE in univariate analysis only |